Search…

Lates News

07/11/2025

In the early trading on Thursday, Pfizer rose 0.5% while Novo Nordisk fell 3%. It was reported that after Novo Nordisk raised its offer to acquire the obesity biotech company Metsera to $10 billion, Pfizer also made a matching offer, raising the valuation to $10 billion, escalating the acquisition competition in the GLP-1 drug field. Metsera, the target of the acquisition, surged 10.5% in early trading on Thursday.

Latest

2 m ago

On Thursday, the overnight reverse repurchase agreement volume of the Federal Reserve was $107.54 billion, down from $127.00 billion the previous trading day.

3 m ago

Google: Launches three new artificial intelligence updates for sales-side products - Ads Manager, AdSense, and Ads Management.

11 m ago

Novo Nordisk (NVO.N): It is expected that the negative impact on sales in 2026 will be at the lower end of the range of 0%-10%. Performance guidance for 2026 is expected to be disclosed on February 4th.

12 m ago

Nuo and Nuo De: The expected adverse impact on sales in 2026 is expected to be at the lower end of the 0%-10% range. Performance guidance for 2026 is expected to be disclosed on February 4th.

13 m ago

Pirelli CEO: It is expected that the net impact of tariffs in 2026 will be similar to that of 2025, mainly concentrated in the first half of the year.

See all latest